Vanguard Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.82M | Sell |
|
|||||
|
2025
Q1 | $8.15M | Sell |
|
|||||
|
2024
Q4 | $17M | Sell |
|
|||||
|
2024
Q3 | $36.4M | Sell |
|
|||||
|
2024
Q2 | $34.7M | Buy |
|
|||||
|
2024
Q1 | $72.7M | Buy |
|
|||||
|
2023
Q4 | $34.8M | Sell |
|
|||||
|
2023
Q3 | $23.1M | Sell |
|
|||||
|
2023
Q2 | $55.8M | Buy |
|
|||||
|
2023
Q1 | $62.5M | Buy |
|
|||||
|
2022
Q4 | $80.4M | Buy |
|
|||||
|
2022
Q3 | $175M | Buy |
|
|||||
|
2022
Q2 | $192M | Buy |
|
|||||
|
2022
Q1 | $298M | Buy |
|
|||||
|
2021
Q4 | $449M | Buy |
|
|||||
|
2021
Q3 | $452M | Buy |
|
|||||
|
2021
Q2 | $657M | Buy |
|
|||||
|
2021
Q1 | $616M | Buy |
|
|||||
|
2020
Q4 | $616M | Buy |
|
|||||
|
2020
Q3 | $251M | Buy |
|
|||||
|
2020
Q2 | $175M | Buy |
|
|||||
|
2020
Q1 | $72.2M | Buy |
|
|||||
|
2019
Q4 | $61.2M | Buy |
|
|||||
|
2019
Q3 | $47.4M | Buy |
|
|||||
|
2019
Q2 | $55.4M | Buy |
|
|||||
|
2019
Q1 | $47.8M | Buy |
|
|||||
|
2018
Q4 | $32.6M | Buy |
|
|||||
|
2018
Q3 | $39.9M | Buy |
|
|||||
|
2018
Q2 | $24.6M | Buy |
|
|||||
|
2018
Q1 | $17.7M | Buy |
|
|||||
|
2017
Q4 | $8.92M | Buy |
|
|||||
|
2017
Q3 | $5.08M | Buy |
|
|||||
|
2017
Q2 | $4.1M | Buy |
|
|||||
|
2017
Q1 | $5.26M | Buy |
|
|||||
|
2016
Q4 | $1.59M | Sell |
|
|||||
|
2016
Q3 | $2.15M | Buy |
|
|||||
|
2016
Q2 | $1.12M | Buy |
|
|||||
|
2016
Q1 | $1.14M | Buy |
|
|||||
|
2015
Q4 | $1.4M | Buy |
|
|||||
|
2015
Q3 | $1.97M | Buy |
|
|||||
|
2015
Q2 | $2.18M | Buy |
|
|||||
|
2015
Q1 | $883K | Buy |
|
|||||
|
2014
Q4 | $865K | Hold |
|
|||||
|
2014
Q3 | $884K | Buy |
|
|||||
|
2014
Q2 | $938K | Hold |
|
|||||
|
2014
Q1 | $1.45M | Buy |
|
|||||
|
2013
Q4 | $116K | Buy |
|